Wuhan Thalys Med Tech Co Ltd
Thalys Medical Technology Group Corporation provides medical integrated operation and management services in China. It offers automated immunofluorescence analyzer; coagulation reagent; COVID-19 test kit; line blot1 fully automated immunoblotting instrument; and flow products. The company also provides automated coagulation analyzer; automated immunoassay system; automated biochemical analysis sy… Read more
Wuhan Thalys Med Tech Co Ltd (603716) - Net Assets
Latest net assets as of September 2025: CN¥1.05 Billion CNY
Based on the latest financial reports, Wuhan Thalys Med Tech Co Ltd (603716) has net assets worth CN¥1.05 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.09 Billion) and total liabilities (CN¥1.04 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.05 Billion |
| % of Total Assets | 50.39% |
| Annual Growth Rate | 10.79% |
| 5-Year Change | -46.63% |
| 10-Year Change | 104.56% |
| Growth Volatility | 28.7 |
Wuhan Thalys Med Tech Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Wuhan Thalys Med Tech Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Wuhan Thalys Med Tech Co Ltd (2011–2024)
The table below shows the annual net assets of Wuhan Thalys Med Tech Co Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥962.04 Million | -26.82% |
| 2023-12-31 | CN¥1.31 Billion | -12.18% |
| 2022-12-31 | CN¥1.50 Billion | -14.11% |
| 2021-12-31 | CN¥1.74 Billion | -3.31% |
| 2020-12-31 | CN¥1.80 Billion | +11.20% |
| 2019-12-31 | CN¥1.62 Billion | -0.28% |
| 2018-12-31 | CN¥1.63 Billion | +61.95% |
| 2017-12-31 | CN¥1.00 Billion | +16.81% |
| 2016-12-31 | CN¥859.29 Million | +82.71% |
| 2015-12-31 | CN¥470.30 Million | +15.84% |
| 2014-12-31 | CN¥405.99 Million | +17.35% |
| 2013-12-31 | CN¥345.97 Million | +16.68% |
| 2012-12-31 | CN¥296.50 Million | +16.78% |
| 2011-12-31 | CN¥253.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Wuhan Thalys Med Tech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 41.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥45.01 Million | 4.82% |
| Common Stock | CN¥190.99 Million | 20.44% |
| Other Components | CN¥698.29 Million | 74.74% |
| Total Equity | CN¥934.29 Million | 100.00% |
Wuhan Thalys Med Tech Co Ltd Competitors by Market Cap
The table below lists competitors of Wuhan Thalys Med Tech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SIA ENGINEERING CO.
F:O3H
|
$541.08 Million |
|
Henan Tong-Da Cable Co Ltd
SHE:002560
|
$541.36 Million |
|
VITASOY INTL
MU:VS6
|
$541.44 Million |
|
Taiyuan Heavy Industry Co Ltd
SHG:600169
|
$541.60 Million |
|
ARGAN EO 2
F:871
|
$540.98 Million |
|
CanSino Biologics Inc
PINK:CASBF
|
$540.94 Million |
|
R R Kabel Limited
NSE:RRKABEL
|
$540.71 Million |
|
CANWEL BLDG MATL
F:2CW
|
$540.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Wuhan Thalys Med Tech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,210,913,086 to 934,292,086, a change of -276,621,000 (-22.8%).
- Net loss of 209,239,667 reduced equity.
- Dividend payments of 59,879,030 reduced retained earnings.
- Share repurchases of 29,721,173 reduced equity.
- Other factors increased equity by 22,218,870.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-209.24 Million | -22.4% |
| Dividends Paid | CN¥59.88 Million | -6.41% |
| Share Repurchases | CN¥29.72 Million | -3.18% |
| Other Changes | CN¥22.22 Million | +2.38% |
| Total Change | CN¥- | -22.84% |
Book Value vs Market Value Analysis
This analysis compares Wuhan Thalys Med Tech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.69x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 11.79x to 4.69x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥1.93 | CN¥22.82 | x |
| 2012-12-31 | CN¥2.25 | CN¥22.82 | x |
| 2013-12-31 | CN¥2.55 | CN¥22.82 | x |
| 2014-12-31 | CN¥2.99 | CN¥22.82 | x |
| 2015-12-31 | CN¥3.45 | CN¥22.82 | x |
| 2016-12-31 | CN¥4.75 | CN¥22.82 | x |
| 2017-12-31 | CN¥5.27 | CN¥22.82 | x |
| 2018-12-31 | CN¥7.91 | CN¥22.82 | x |
| 2019-12-31 | CN¥7.55 | CN¥22.82 | x |
| 2020-12-31 | CN¥8.47 | CN¥22.82 | x |
| 2021-12-31 | CN¥8.19 | CN¥22.82 | x |
| 2022-12-31 | CN¥7.35 | CN¥22.82 | x |
| 2023-12-31 | CN¥6.26 | CN¥22.82 | x |
| 2024-12-31 | CN¥4.87 | CN¥22.82 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Wuhan Thalys Med Tech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -22.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -11.56%
- • Asset Turnover: 0.64x
- • Equity Multiplier: 3.03x
- Recent ROE (-22.40%) is below the historical average (3.93%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 14.99% | 19.50% | 0.62x | 1.25x | CN¥12.58 Million |
| 2012 | 13.05% | 13.54% | 0.73x | 1.32x | CN¥8.96 Million |
| 2013 | 14.32% | 12.51% | 0.90x | 1.28x | CN¥14.79 Million |
| 2014 | 14.16% | 12.70% | 0.83x | 1.35x | CN¥16.59 Million |
| 2015 | 13.34% | 11.60% | 0.80x | 1.44x | CN¥15.39 Million |
| 2016 | 8.17% | 10.99% | 0.57x | 1.30x | CN¥-15.44 Million |
| 2017 | 10.05% | 10.20% | 0.59x | 1.68x | CN¥508.77K |
| 2018 | 6.19% | 7.15% | 0.51x | 1.70x | CN¥-57.92 Million |
| 2019 | 7.41% | 6.03% | 0.61x | 2.02x | CN¥-38.50 Million |
| 2020 | 4.98% | 3.86% | 0.54x | 2.37x | CN¥-82.73 Million |
| 2021 | -2.46% | -1.48% | 0.61x | 2.75x | CN¥-194.59 Million |
| 2022 | -13.63% | -8.28% | 0.58x | 2.81x | CN¥-331.56 Million |
| 2023 | -13.10% | -7.90% | 0.60x | 2.76x | CN¥-279.66 Million |
| 2024 | -22.40% | -11.56% | 0.64x | 3.03x | CN¥-302.67 Million |
Industry Comparison
This section compares Wuhan Thalys Med Tech Co Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $2,767,087,259
- Average return on equity (ROE) among peers: 6.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Wuhan Thalys Med Tech Co Ltd (603716) | CN¥1.05 Billion | 14.99% | 0.98x | $541.06 Million |
| Berry Genomics Co Ltd (000710) | $108.87 Million | -46.67% | 1.22x | $377.87 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $9.50 Billion | 15.09% | 1.22x | $1.14 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $1.70 Billion | 17.66% | 0.10x | $317.93 Million |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $308.32 Million | 33.58% | 0.53x | $283.14 Million |
| Maccura Biotechnology Co Ltd (300463) | $4.54 Billion | 21.06% | 0.45x | $576.46 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $4.05 Billion | -16.18% | 0.14x | $319.65 Million |
| BGI Genomics Co Ltd (300676) | $4.25 Billion | 9.09% | 0.23x | $1.45 Billion |
| Amoy Diagnostics Co Ltd (300685) | $307.91 Million | 21.77% | 0.15x | $834.75 Million |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $1.82 Billion | -6.01% | 0.44x | $226.85 Million |
| SMO ClinPlus Co. Ltd. (301257) | $1.08 Billion | 12.47% | 0.26x | $347.98 Million |